09:08 AM EST, 11/15/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Friday that a European Medicines Agency committee has recommended the approval of Opdivo in combination with Yervoy for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Results from the CheckMate -8HW study demonstrated a reduction in risk of disease progression or death by 79% relative to chemotherapy in the patient population, the company said.

The recommendation by the Committee for Medicinal Products for Human Use will now be reviewed by the European Commission before a final decision is made, Bristol-Myers added.

Price: 54.52, Change: +0.20, Percent Change: +0.37